Tim is an experienced business writer having written for three decades at major business publications, specializing in banking, accounting, resources, technology, telecoms, agriculture, property trusts and - of course - the life sciences.
Tim was best known as the writer of the Criterion investment column analyzing ASX-listed companies in a style accessible to retail investors. A quirk of the column was that it offered 'buy' and 'sell' recommendations in a journalist context.
Tim is proud to have no financial qualifications other than an outdated Certificate in Financial Markets and a dedicated following from investors, brokers and analysts and says he is yet to be charged by ASIC despite penning Criterion for more than 10 years.
Tim holds a Bachelor of Arts in Journalism from the Royal Melbourne Institute of Technology.
Emvision Medical Devices (Oct 4, 2024)
Cynata Therapeutics (Sep 27, 2024)
Medical Developments (Sep 13, 2024)
Telix Pharmaceuticals (Aug 30, 2024)
Arovella Therapeutics (Aug 9, 2024)
Actinogen Medical (Aug 2, 2024)
Aroa Biosurgery (Jul 26, 2024)
Starpharma Holdings (Jul 5, 2024)
Radiopharm Theranostics (Jun 28, 2024)
Neurotech International (Jun 21, 2024)
Island Pharmaceuticals (Jun 14, 2024)
Genetic Signatures (Jun 7, 2024)
Amplia Therapeutics (May 31, 2024)
Proteomics International Labs (May 24, 2024)
Bcal Diagnostics (Apr 12, 2024)
Universal Biosensors (Mar 28, 2024)
Neuren Pharmaceuticals (Mar 8, 2024)
End Of Year Report Card (Dec 15, 2023)
Botanix Pharmaceuticals (Dec 8, 2023)
Optiscan Imaging Ltd (Nov 24, 2023)
PYC Therapeutics (Nov 17, 2023)
Paradigm Biopharmaceuticals (Nov 3, 2023)
Argenica Therapeutics (Sep 22, 2023)
Clarity Pharmaceuticals (Sep 15, 2023)
Cleo Diagnostics (Aug 25, 2023)
Telix Pharmaceuticals (Jul 28, 2023)
Cynata Therapeutics (Jul 21, 2023)
Arovella Therapeutics (Jul 14, 2023)
Microba Life Sciences (Jul 7, 2023)
Lumos Diagnostics (Jun 16, 2023)
Nova Eye Medical (Jun 9, 2023)
EBR Systems Inc (May 26, 2023)
Chimeric Therapeutics (May 19, 2023)
Control Bionics (Apr 28, 2023)
Volpara Health Technologies (Apr 21, 2023)
Radiopharm Theranostics (Apr 6, 2023)
Neuren Pharmaceuticals (Mar 17, 2023)
* Disclosure:
Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. Nor is he a licenced financial adviser.
Subscribe to Biotech Daily
© Copyright 2007-2022. All Rights Reserved. Biotech Daily, PO Box 5000, Carlton, Victoria